Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become
clinically available in some countries, which has greatly increased the need for biomarker …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Aggregated insoluble tau is one of two defining features of Alzheimer's disease. Because
clinical symptoms are strongly correlated with tau aggregates, drug development and …

Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for …

Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Several promising plasma biomarkers for Alzheimer's disease have been recently
developed, but their neuropathological correlates have not yet been fully determined. To …

Aging, as a complex process involving multiple cellular and molecular pathways, is known to
be exacerbated by various stresses. Because responses to these stresses, such as oxidative …

Biological staging of individuals with Alzheimer's disease (AD) may improve diagnostic and
prognostic workup of dementia in clinical practice and the design of clinical trials. In this …

Alzheimer's disease (AD) is a complex, progressive primary neurodegenerative disease.
Since pivotal genetic studies in 1993, the ε4 allele of the apolipoprotein E gene (APOE ε4) …